» Articles » PMID: 35286625

Effect of Chest Physiotherapy on Cystic Fibrosis Sputum Nanostructure: an Experimental and Theoretical Approach

Abstract

Cystic fibrosis (CF) is a disease characterized by the production of viscous mucoid secretions in multiple organs, particularly the airways. The pathological increase of proteins, mucin and biological polymers determines their arrangement into a three-dimensional polymeric network, affecting the whole mucus and impairing the muco-ciliary clearance which promotes inflammation and bacterial infection. Thus, to improve the efficacy of the drugs usually applied in CF therapy (e.g., mucolytics, anti-inflammatory and antibiotics), an in-depth understanding of the mucus nanostructure is of utmost importance. Drug diffusivity inside a gel-like system depends on the ratio between the diffusing drug molecule radius and the mesh size of the network. Based on our previous findings, we propose the combined use of rheology and low field NMR to study the mesh size distribution of the sputum from CF patients. Specifically, we herein explore the effects of chest physiotherapy on CF sputum characteristic as evaluated by rheology, low field NMR and the drug penetration through the mucus via mathematical simulation. These data show that chest physiotherapy has beneficial effects on patients, as it favourably modifies sputum and enhances drug penetration through the respiratory mucus.

Citing Articles

Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases.

Abrami M, Biasin A, Tescione F, Tierno D, Dapas B, Carbone A Int J Mol Sci. 2024; 25(3).

PMID: 38339210 PMC: 10856136. DOI: 10.3390/ijms25031933.


Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers.

Pangeni R, Meng T, Poudel S, Sharma D, Hutsell H, Ma J Int J Pharm. 2023; 634:122661.

PMID: 36736964 PMC: 9975059. DOI: 10.1016/j.ijpharm.2023.122661.

References
1.
Farrell P . The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008; 7(5):450-3. DOI: 10.1016/j.jcf.2008.03.007. View

2.
Ciofu O, Tolker-Nielsen T, Jensen P, Wang H, Hoiby N . Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv Drug Deliv Rev. 2014; 85:7-23. DOI: 10.1016/j.addr.2014.11.017. View

3.
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R . Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34(2):91-100. DOI: 10.1002/ppul.10127. View

4.
Fyfe J, Govan J . Alginate synthesis in mucoid Pseudomonas aeruginosa: a chromosomal locus involved in control. J Gen Microbiol. 1980; 119(2):443-50. DOI: 10.1099/00221287-119-2-443. View

5.
Govan J, Deretic V . Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996; 60(3):539-74. PMC: 239456. DOI: 10.1128/mr.60.3.539-574.1996. View